Literature DB >> 8881626

Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children.

J M Malinovsky1, F Servin, A Cozian, J Y Lepage, M Pinaud.   

Abstract

It has been suggested that nasal administration of ketamine may be used to induce anaesthesia in paediatric patients. We have examined the pharmacokinetics of ketamine and norketamine after nasal administration compared with rectal and i.v. administration in young children. During halothane anaesthesia, 32 children, aged 2-9 yr, weight 10-30 kg, were allocated randomly to receive ketamine 3 mg kg-1 nasally (group IN3) or ketamine 9 mg kg-1 nasally (group IN9); ketamine 9 mg kg-1 rectally (group IR9); or ketamine 3 mg kg-1 i.v. (group IV3). Venous blood samples were obtained before and up to 360 min after administration of ketamine. Plasma concentrations of ketamine and norketamine were measured by gas liquid chromatography. Statistical comparisons were performed using ANOVA and the Kruskall-Wallis test, with P < 0.05 as significant. Mean plasma concentrations of ketamine peaked at 496 ng ml-1 in group IN3 within 20 min, 2104 ng ml-1 in group IN9 within 21 min, and 632 ng ml-1 in group IR9 within 42 min. Plasma concentrations of norketamine peaked at approximately 120 min after nasal ketamine, but appeared more rapidly after rectal administration of ketamine and were always higher than ketamine concentrations in the same situation. Calculated bioavailability was 0.50 in groups IN3 and IN9 and 0.25 in group IR9. We conclude that nasal administration of low doses of ketamine produced plasma concentrations associated with analgesia, but using high doses via the nasal route produced high plasma concentrations of ketamine similar to those that induce anaesthesia. However, the large volume of ketamine required was partly swallowed and led to an unacceptable variability of effect that precludes this route for induction of anaesthesia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8881626     DOI: 10.1093/bja/77.2.203

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  39 in total

1.  Intranasal delivery--modification of drug metabolism and brain disposition.

Authors:  Yin Cheong Wong; Zhong Zuo
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

Review 2.  The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders.

Authors:  D S Quintana; A J Guastella; L T Westlye; O A Andreassen
Journal:  Mol Psychiatry       Date:  2015-11-10       Impact factor: 15.992

Review 3.  Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment.

Authors:  Jason Ng; Leanna M W Lui; Joshua D Rosenblat; Kayla M Teopiz; Orly Lipsitz; Danielle S Cha; Jiaqi Xiong; Flora Nasri; Yena Lee; Kevin Kratiuk; Nelson B Rodrigues; Hartej Gill; Mehala Subramaniapillai; Rodrigo B Mansur; Roger Ho; Bing Cao; Roger S McIntyre
Journal:  Psychopharmacology (Berl)       Date:  2021-01-23       Impact factor: 4.530

4.  Comparison between intranasal dexmedetomidine and intranasal ketamine as premedication for procedural sedation in children undergoing MRI: a double-blind, randomized, placebo-controlled trial.

Authors:  Prakhar Gyanesh; Rudrashish Haldar; Divya Srivastava; Prashant Mohan Agrawal; Akhilesh Kumar Tiwari; P K Singh
Journal:  J Anesth       Date:  2013-06-26       Impact factor: 2.078

Review 5.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 6.  Ketamine: The final frontier or another depressing end?

Authors:  Omar K Sial; Eric M Parise; Lyonna F Parise; Tamara Gnecco; Carlos A Bolaños-Guzmán
Journal:  Behav Brain Res       Date:  2020-02-01       Impact factor: 3.332

Review 7.  Esketamine: a glimmer of hope in treatment-resistant depression.

Authors:  Upinder Kaur; Bhairav Kumar Pathak; Amit Singh; Sankha Shubhra Chakrabarti
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-11-19       Impact factor: 5.270

8.  Effect of a short-term fast on ketamine-xylazine anesthesia in rats.

Authors:  Maggie B Struck; Karl A Andrutis; Harvey E Ramirez; August H Battles
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-05       Impact factor: 1.232

9.  Ketamine induces motor neuron toxicity and alters neurogenic and proneural gene expression in zebrafish.

Authors:  Jyotshna Kanungo; Elvis Cuevas; Syed F Ali; Merle G Paule
Journal:  J Appl Toxicol       Date:  2011-11-02       Impact factor: 3.446

Review 10.  Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy.

Authors:  Marko A Peltoniemi; Nora M Hagelberg; Klaus T Olkkola; Teijo I Saari
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.